The Malaghan Institute is committed to building a New Zealand platform and pipeline for RNA nanomedicine, using the technology behind the Pfizer-BioNTech COVID-19 vaccine.
COVID-19 vaccines are just the tip of the iceberg for what RNA nanotechnology offers, with enormous potential for therapeutic development not just for human medicine but also for treatments that will impact our primary industries.
Thanks to donor funding, the Malaghan Institute has already secured key technology platforms to allow for the production and encapsulation of RNA nanomedicines in lipid nanoparticles. Using this technology, the process of designing, developing and manufacturing vaccines and other therapeutics is made efficient and effective.
RNA nanotechnology presents a significant opportunity for New Zealand to supercharge its biotech sector, become a leader in the development of novel RNA therapeutics and provide vaccine security in the face of future pandemics. It offers the potential to develop real-world solutions for New Zealand specific problems, including diseases that disproportionately affect our Māori and Pasifika populations.
The Institute is working closely with Government and local and international partners to continue to build New Zealand’s capability to develop, manufacture and commercialise breakthrough RNA therapeutics.
Investment in RNA technology will boost NZ science and biotech capability
19 May 2022
International Day of Immunology 2022: Vaccine research enters a new era with mRNA technology
29 April 2022
NZ needs action now on nanomedicines hub
20 April 2022
Nanoparticle tech paves way for home-grown vaccines and therapeutics
27 January 2022
mRNA vaccines: how they work
29 November 2021
Taking RNA technology into NZ’s future
19 October 2021